TCGA-EW-A1IW-01A-11R-A13Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.420
- TNFA_SIGNALING_VIA_NFKB+0.380
- G2M_CHECKPOINT+0.370
- ANDROGEN_RESPONSE+0.350
- UV_RESPONSE_DN+0.310
- TGF_BETA_SIGNALING+0.290
- ESTROGEN_RESPONSE_EARLY+0.250
- NOTCH_SIGNALING+0.250
- IL6_JAK_STAT3_SIGNALING+0.240
- ESTROGEN_RESPONSE_LATE+0.230
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.280
- GLYCOLYSIS-0.190
- ALLOGRAFT_REJECTION-0.160
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.150
- UNFOLDED_PROTEIN_RESPONSE-0.120
- BILE_ACID_METABOLISM-0.050
- HEDGEHOG_SIGNALING-0.050
- OXIDATIVE_PHOSPHORYLATION-0.050
- COMPLEMENT+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD032263_D1.RNA-Seq | EPN | Anaplastic EPN | 0.743 |
| 2 | TCGA-56-7582-01A-11R-2045-07 | — | cohortSQ2 | 0.735 |
| 3 | SRR27320688 | — | — | 0.709 |
| 4 | TCGA-CV-7245-01A-11R-2016-07 | — | — | 0.696 |
| 5 | MNG983 | — | — | 0.690 |
| 6 | TCGA-BH-A0E2-01A-11R-A056-07 | — | B | 0.687 |
| 7 | TCGA-77-7338-01A-11R-2045-07 | — | cohortSQ2 | 0.680 |
| 8 | MNG683 | — | — | 0.677 |
| 9 | TCGA-CR-7390-01A-11R-2016-07 | — | — | 0.676 |
| 10 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.674 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |